Matheu Wilson

Matheu Wilson supports the Centers for Disease Control and Prevention’s Office of Acquisition Services in executing mission-critical procurements that advance public health infrastructure. Responsible for managing complex acquisitions in pharmaceutical manufacturing and scientific consulting services, Wilson ensures timely delivery of diagnostics, laboratory supplies, and technical expertise essential to infectious disease surveillance and response. Their work directly enables CDC’s operational readiness by securing high-integrity products and services that support clinical testing, epidemiological analysis, and biodefense preparedness, aligning procurement strategy with national health security priorities. Wilson maintains sustained contracting relationships with leading providers in the public health sector, including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, and Cepheid. These partnerships reflect a focus on high-reliability vendors capable of delivering GMP-compliant pharmaceuticals, advanced diagnostic platforms, and specialized scientific services under stringent regulatory frameworks. The working relationship pattern emphasizes performance-based contracting, long-term vendor engagement, and strict adherence to quality assurance protocols, particularly in biosafety and laboratory accreditation standards. Wilson’s procurement portfolio reflects a strong preference for full and open competition, with 100% of awards issued without set-asides for 8(a), HUBZone, or SDVOSB programs. This approach prioritizes technical capability and mission-critical performance over socioeconomic preferences, consistent with the agency’s need for rapid, scalable, and scientifically validated solutions in high-stakes public health emergencies. The primary procurement focus lies in NAICS 325412 (Pharmaceutical Preparation Manufacturing), reflecting dominant demand for diagnostic reagents, vaccine components, and clinical-grade biologics. Secondary emphasis on NAICS 541690 (Other Scientific and Technical Consulting Services) underscores reliance on expert contractors for assay development, data modeling, and laboratory capacity building. Wilson’s expertise centers on procuring complex, regulated biomedical products and services that require compliance with FDA, CLIA, and CDC biosafety guidelines.